Eosinophilic inflammation, commonly associated with asthma and chronic obstructive pulmonary disease (COPD), is often treatable. A new study has aimed to determine whether benralizumab is more effective than prednisolone in managing eosinophilic exacerbations. In the study, 158 patients with eosinophilic exacerbation of asthma or COPD were randomly assigned to receive benralizumab or prednisolone. Remarkably, benralizumab achieved fewer treatment failures (45%) than prednisolone (74%) at 90 days of treatment.
In addition, benralizumab improved visual analog scale scores compared to prednisolone at 28 days. Notably, adverse events, such as sinusitis or sinus infection and hyperglycemia, were reported only in the prednisolone group. These findings suggest that benralizumab is a superior treatment option for acute eosinophilic exacerbation of asthma and COPD compared to prednisolone.…
